Sangamo Therapeutics Signs a Research Evaluation and Option Agreement with Prevail, a Wholly Owned Subsidiary of Lilly for Novel Engineered Capsids
Shots:
- Sangamo will be eligible to receive exercise fees and developmental milestones of ~$415M and commercial milestones of ~$775M along with royalties based on net sales of Prevail products incorporating the licensed capsids, If Prevail exercises its option for all targets, and a Prevail product is approved in the US and EU for each target
- Prevail gets the rights to evaluate proprietary AAV capsids (developed by Sangamo) in in vitro and in vivo studies and may exercise certain options to license these capsids for multiple undisclosed neurological targets
- Prevail will lead for further development, manufacturing, and commercialization of products incorporating the licensed capsids
Ref: Businesswire | Image: Sangamo
Reated News:- Sangamo Therapeutics Reports Results of ST-920 in P-I/II (STAAR) Study for the Treatment of Fabry Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
